Commission File Number: 001-40443 Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION and telephone number, including area code) Singular Genomics Systems, Inc. Securities registered pursuant to Section ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-40443 Singular Genomics Systems, Inc. (Exact name of Registrant as specified in its charter) (State or other jurisdiction ...

Singular Genomics Systems, Inc. (NASDAQ:OMIC) Q4 2022 Earnings Conference Call March 2, 2023 4:30 PM ET Company Participants Philip Taylor - Investor Relations Drew Spaventa - Founder and Chief Executive Officer Dalen Meeter - Chief Financial Officer Conference Call Participants John Sourbeer - UBS Matt Sykes - Goldman Sachs Daniel Brennan - Cowen & Co. Operator Greetings, and welcome to the Singular Genomics Systems, Incorporated Fourth Quarter 2022 Earnings Conference Call.[Operator Instructions] Please n ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___. Commission File Number 001-40443 Singular Genomics Systems, Inc. (Exact name of Registrant as specified in its Charter) Delaware 81-2948451 (State or other jurisdic ...

Singular Genomics Systems, Inc. (NASDAQ:OMIC) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations Bruce Spaventa - Founder and Chief Executive Officer Dalen Meeter - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Tom Stevens - Cowen John Sourbeer - UBS Operator Good day, ladies and gentlemen and welcome to the Singular Genomics Systems, Inc. Third Quarter 2022 Earnings Conference Call. [Operator Instructions] I ...

Part I [Financial Statements (Unaudited)](index=5&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) The company reported a net loss of **$69.8 million** for the nine months ended September 30, 2022, with **$263.8 million** in cash and an accumulated deficit of **$221.7 million** [Notes to Condensed Financial Statements](index=11&type=section&id=Notes%20to%20Condensed%20Financial%20Statements) The notes detail the company's business as a life science technology firm developing sequencing technologies, highlighting its June 2021 IPO, adoption of ASC 842 for leases, and significant future lease commitments including a **$179.0 million** headquarters lease - The company develops next-generation sequencing technologies, with its commercially available **G4 Sequencing Platform** and the in-development **PX** system for multiomics[34](index=34&type=chunk) - The company believes its cash, cash equivalents, and short-term investments of **$263.8 million** as of September 30, 2022, are sufficient to fund operations for at least the next 12 months[37](index=37&type=chunk) - Effective January 1, 2022, the company adopted ASC 842, Leases, resulting in the recognition of **$7.1 million** in operating lease liabilities and **$6.4 million** in right-of-use lease assets[57](index=57&type=chunk) - The company has a significant future commitment for a new headquarters (OAS Lease), which has not yet commenced but has total undiscounted future minimum lease payments of approximately **$179.0 million**[89](index=89&type=chunk) - As of September 30, 2022, the company had **$10.5 million** in long-term debt outstanding under its loan agreement with Silicon Valley Bank (SVB). An amendment extended the drawdown period for an additional **$25.0 million** to March 31, 2024, contingent on a revenue hurdle[67](index=67&type=chunk)[69](index=69&type=chunk)[70](index=70&type=chunk) Condensed Balance Sheet Data (in thousands) | Account | Sep 30, 2022 | Dec 31, 2021 | | :--- | :--- | :--- | | **Assets** | | | | Cash, cash equivalents & short-term investments | $263,840 | $339,223 | | Total current assets | $286,114 | $347,760 | | Total assets | $345,475 | $355,648 | | **Liabilities & Equity** | | | | Total current liabilities | $14,178 | $6,744 | | Total liabilities | $68,550 | $19,475 | | Accumulated deficit | $(221,674) | $(151,896) | | Total stockholders' equity | $276,925 | $336,173 | Condensed Statement of Operations Data (in thousands, except per share data) | Account | Nine Months Ended Sep 30, 2022 | Nine Months Ended Sep 30, 2021 | | :--- | :--- | :--- | | Research and development | $35,439 | $23,200 | | Selling, general and administrative | $35,518 | $18,406 | | Loss from operations | $(70,957) | $(41,606) | | Net loss | $(69,778) | $(79,011) | | Basic and diluted net loss per share | $(0.98) | $(2.05) | Condensed Statement of Cash Flows Data (in thousands) | Account | Nine Months Ended Sep 30, 2022 | Nine Months Ended Sep 30, 2021 | | :--- | :--- | :--- | | Net cash used in operating activities | $(67,177) | $(36,002) | | Net cash used in investing activities | $(39,737) | $(107,536) | | Net cash provided by financing activities | $151 | $371,318 | | Net (decrease) increase in cash | $(106,763) | $227,780 | [Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)](index=27&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's pre-revenue status, significant operating losses due to R&D and commercialization investments, and strong liquidity with **$263.8 million** in cash expected to fund operations for at least 12 months - The company is executing a commercialization plan for its **G4** sequencer, which launched in December 2021, and is developing its second product, the **PX** multiomics platform, with a technology access program planned for Q4 2022[114](index=114&type=chunk)[115](index=115&type=chunk) - The company expects expenses to increase significantly due to the commercialization of the **G4**, development of the **PX**, expansion of sales and manufacturing infrastructure, and hiring of qualified personnel[119](index=119&type=chunk) - Although **G4** shipments began in Q2 2022, the company has not yet recognized revenue, as it is contingent upon meeting customer acceptance criteria[121](index=121&type=chunk)[163](index=163&type=chunk) - The company filed a shelf registration statement on Form S-3 in July 2022, allowing it to offer up to **$250 million** in securities, including an 'at the market' offering of up to **$100 million** in common stock, to provide future capital flexibility[144](index=144&type=chunk) [Results of Operations](index=30&type=section&id=Results%20of%20Operations) The company's loss from operations increased significantly for both the three and nine-month periods ended September 30, 2022, driven by higher R&D and SG&A expenses due to increased personnel and facility costs Comparison of Operating Expenses (in thousands) | Expense Category | Three Months Ended Sep 30, 2022 | Three Months Ended Sep 30, 2021 | % Change | | :--- | :--- | :--- | :--- | | Research and development | $12,732 | $8,910 | 43% | | Selling, general and administrative | $11,962 | $8,551 | 40% | | **Loss from operations** | **$(24,694)** | **$(17,461)** | **41%** | | | **Nine Months Ended Sep 30, 2022** | **Nine Months Ended Sep 30, 2021** | **% Change** | | Research and development | $35,439 | $23,200 | 53% | | Selling, general and administrative | $35,518 | $18,406 | 93% | | **Loss from operations** | **$(70,957)** | **$(41,606)** | **71%** | - For the nine months ended Sep 30, 2022, R&D expenses increased by **$12.2 million (53%)** YoY, primarily due to a **$6.1 million** increase in employee compensation costs and a **$3.5 million** increase in facility and IT costs[136](index=136&type=chunk) - For the nine months ended Sep 30, 2022, SG&A expenses increased by **$17.1 million (93%)** YoY, driven by a **$10.3 million** rise in employee compensation and a **$3.5 million** increase in professional fees related to being a public company[138](index=138&type=chunk) [Liquidity and Capital Resources](index=32&type=section&id=Liquidity%20and%20Capital%20Resources) The company held **$263.8 million** in cash as of September 30, 2022, sufficient for 12 months of operations, despite increased cash used in operating activities and significant future lease and debt obligations - As of September 30, 2022, the company held **$263.8 million** in cash, cash equivalents, and short-term investments, with an accumulated deficit of **$221.7 million**[140](index=140&type=chunk) - Future capital obligations include minimum lease payments of **$6.5 million** in 2023 and **$259.0 million** thereafter, and debt payments of **$0.7 million** in 2023 and **$12.2 million** thereafter[141](index=141&type=chunk) Cash Flow Summary (in thousands) | Cash Flow Activity | Nine Months Ended Sep 30, 2022 | Nine Months Ended Sep 30, 2021 | | :--- | :--- | :--- | | Net cash used in operating activities | $(67,177) | $(36,002) | | Net cash used in investing activities | $(39,737) | $(107,536) | | Net cash provided by financing activities | $151 | $371,318 | [Quantitative and Qualitative Disclosures about Market Risk](index=38&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company reported no substantial changes to its market risks during the quarter ended September 30, 2022, compared to its prior annual report - There were no substantial changes to the company's market risks during the quarter ended September 30, 2022[176](index=176&type=chunk) [Controls and Procedures](index=38&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of September 30, 2022, with no material changes to internal control over financial reporting during the quarter - Management concluded that as of September 30, 2022, the company's disclosure controls and procedures were effective[177](index=177&type=chunk) - No material changes to the company's internal control over financial reporting occurred during the quarter[178](index=178&type=chunk) Part II [Legal Proceedings](index=39&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently a party to any material legal proceedings but acknowledges potential involvement in future ordinary course business litigation - As of the filing date, the company is not a party to any material legal proceedings[182](index=182&type=chunk) [Risk Factors](index=40&type=section&id=Item%201A.%20Risk%20Factors) The company faces extensive risks including limited operating history, significant losses, dependence on G4 commercialization and PX development, intense competition, supply chain issues, and intellectual property litigation - The company is a pre-revenue entity with a history of significant losses (**$221.7 million** accumulated deficit as of Sep 30, 2022) and expects losses to continue as it invests in commercialization and R&D[185](index=185&type=chunk) - The business is highly dependent on the successful commercialization of the **G4** instrument and development of the planned **PX**, with noted delays in scaling up the manufacturing process for initial **G4** units[193](index=193&type=chunk) - The company faces intense competition from established players with greater resources, brand recognition, and existing customer relationships[189](index=189&type=chunk)[190](index=190&type=chunk) - Potential litigation over intellectual property is a significant risk, as the company operates in a crowded technology area with numerous patents held by competitors[260](index=260&type=chunk)[261](index=261&type=chunk) - Changes in the regulatory landscape for **Research Use Only (RUO)** products or **Laboratory Developed Tests (LDTs)** by the FDA could subject the company's products to more stringent and costly regulation[296](index=296&type=chunk)[297](index=297&type=chunk) [Use of Proceeds](index=74&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company's June 2021 IPO generated **$237.2 million** in net proceeds, with no material change in the planned use of these funds - The company's IPO in June 2021 resulted in net proceeds of approximately **$237.2 million**[343](index=343&type=chunk) - There has been no material change in the planned use of proceeds from the IPO[343](index=343&type=chunk) [Other Items](index=74&type=section&id=Other%20Items) The company reported no defaults on senior securities, no mine safety disclosures, and no other information required under Item 5 for the period - The company reported 'None' for Item 3 (Defaults Upon Senior Securities), Item 4 (Mine Safety Disclosures), and Item 5 (Other Information)[344](index=344&type=chunk)[345](index=345&type=chunk)[346](index=346&type=chunk)

Singular Genomics Systems, Inc. (NASDAQ:OMIC) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - Founder & CEO Dalen Meeter - Head, Finance Eli Glezer - Founder and Chief Scientific Officer Conference Call Participants Dan Brennan - Cowen Matt Sykes - Goldman Sachs Michael Ryskin - Bank of America Operator Good day, ladies and gentlemen, and welcome to the Singular Genomics Systems, Incorporated Second Quarter 2022 Earnings Conference Call. At ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-40443 Singular Genomics Systems, Inc. (Exact name of Registrant as specified in its charter) (State or other jurisdiction ...

Singular Genomics Systems, Inc. (NASDAQ:OMIC) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations Drew Spaventa - Founder and Chief Executive Officer Dalen Meeter - Head, Finance Eli Glezer - Founder and Chief Scientific Officer Conference Call Participants Matt Sykes - Goldman Sachs Michael Ryskin - Bank of America John Sourbeer - UBS Tom Stevens - Cowen Operator Good afternoon, ladies and gentlemen, and welcome to the Singular Genomics’ First Qu ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-40443 SINGULAR GENOMICS SYSTEMS, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction ...